Antag Therapeutics
Antag Therapeutics is a biopharmaceutical company focused on developing innovative treatments for obesity. The company is advancing its clinical pipeline with AT-7687, a novel, once-weekly subcutaneous therapy that targets the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) to aid in weight loss. Based in Copenhagen, Denmark, Antag Therapeutics is committed to expanding its portfolio of injectable therapies to address metabolic disorders.
Leadership & Board
- Current Number of Employees
- 23
- Current LinkedIn Followers
- 4,788
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $164M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $80M
- Latest Funding Round
- Series A
- Post-Money Valuation
- ―
Employee Trend
Antag Therapeutics had 23 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Antag Therapeutics had 4,788 followers as of October 12, 2026. The number of followers increased by 33 (0.69%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series A | $80.00M | ― |
| Jan 04, 2025 | Series A | $84.10M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Longview Ventures | Series A |
| Novo Holdings | Series A |
| SR One | Series A |
| Versant Ventures | Series A (2) |
| Dawn Biopharma | Series A |
| Pictet | Series A |
| Export and Investment Fund of Denmark | Series A |
Similar Companies
A snapshot of private companies similar to Antag Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
